Segall Bryant & Hamill LLC reduced its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 12.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 306,352 shares of the biotechnology company's stock after selling 44,987 shares during the quarter. Segall Bryant & Hamill LLC owned 0.13% of ADMA Biologics worth $5,254,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Larson Financial Group LLC bought a new stake in shares of ADMA Biologics in the 3rd quarter worth approximately $31,000. GAMMA Investing LLC boosted its holdings in ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 967 shares in the last quarter. National Bank of Canada FI bought a new position in ADMA Biologics in the 3rd quarter worth $35,000. Vision Financial Markets LLC bought a new position in ADMA Biologics in the fourth quarter worth about $51,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of ADMA Biologics in the 3rd quarter worth approximately $62,000. 75.68% of the stock is owned by hedge funds and other institutional investors.
ADMA Biologics Stock Down 2.8 %
Shares of ADMA traded down $0.58 during trading hours on Monday, hitting $19.69. The company had a trading volume of 2,523,084 shares, compared to its average volume of 3,513,817. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock has a market capitalization of $4.65 billion, a price-to-earnings ratio of 70.37 and a beta of 0.60. ADMA Biologics, Inc. has a 52-week low of $5.90 and a 52-week high of $23.64. The firm has a fifty day moving average price of $17.13 and a 200-day moving average price of $18.16.
Analyst Upgrades and Downgrades
Separately, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.
Check Out Our Latest Report on ADMA
ADMA Biologics Company Profile
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Stories
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
